Key result
SGLT2 inhibitors achieve ~97% persistence in chronic heart failure alongside increased sacubitril/valsartan uptake.
Why the study?
SGLT2 inhibitors are a crucial therapeutic option in HFrEF, but the real-world feasibility of introducing them and their interaction with other recommended drug classes needed evaluation.
What is the real-world feasibility of introducing SGLT2 inhibitors and how does their initiation interact with other disease-modifying heart failure medications in patients with chronic heart failure?
Cohort (n=350)
No
What is the real-world feasibility of introducing SGLT2 inhibitors and how does their initiation interact with other disease-modifying heart failure medications in patients with chronic heart failure?
In real-world clinical practice, SGLT2 inhibitors can be initiated in the vast majority of HFrEF patients with high tolerability, facilitating concurrent optimization of sacubitril/valsartan and reduction of loop diuretic requirements.
Answers are grounded in this paper and cite their sources.
Supports high SGLT2 inhibitor uptake and persistence in HFrEF; extends observational data on GDMT optimization but remains hypothesis-generating.
BACKGROUND: The sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as a crucial therapeutic option for patients with chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate, in a real-world population from a single centre, the feasibility of introducing SGLT2i and their interaction with other recommended drug classes. METHODS: Consecutive patients affected by chronic heart failure (CHF) were evaluated beginning in January 2022. At the baseline clinical visit, both the patient's current medication and the prescribed treatments were recorded. Over a 6- to 12-month follow-up, changes in concomitant therapy were analysed. RESULTS: At baseline, among 350 patients evaluated, only 17 (5%) were already taking SGLT2i: 13 with HFrEF, five with mildly reduced (HFmrEF), preserved (HFpEF) or improved (HFimpEF) ejection fraction. After the baseline assessment, SGLT2i were prescribed to 224 (64%) of the patients, including 179 (84%) with HFrEF, 27 (42%) with HFmrEF/HFimpEF, and 18 (22%) with HFpEF/HFimpEF. After follow-up, SGLT2i therapy was well tolerated and was associated with a significant increase in sacubitril/valsartan prescriptions and a decrease in diuretic use. Finally, a significant improvement in functional status and left ventricular systolic function after SGLT2i therapy was observed. CONCLUSIONS: In this single-centre, real-world study, SGLT2i were primarily prescribed to HFrEF patients who were already on other recommended drug classes for their treatment. Additionally, there was a noticeable enhancement in the prescribed therapy during a short-term follow-up. These findings further bolster the inclusion of this therapeutic approach in regular clinical practice.
No takes yet. Share an insight, caveat, or question.
Tabella et al. (2023) conducted a cohort in Chronic heart failure (HFrEF, HFmrEF, HFpEF, and HFimpEF) (n=350). SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) vs. Baseline status prior to SGLT2 inhibitor initiation was evaluated on Prescription rate of SGLT2 inhibitors and subsequent variations in concomitant heart failure medications. SGLT2 inhibitors were prescribed to 64% of chronic heart failure patients with 96.9% persistence at 6-12 months, alongside increased sacubitril/valsartan and decreased diuretic use.
Synapse has enriched 10 related papers. Consider them for comparative context: